Joseph Vazzano, Chief Financial Officer at Abeona Therapeutics Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Joseph (Joe) Vazzano joined Abeona as Chief Financial Officer in March 2022. Before joining Abeona, he served as Chief Financial Officer of Avenue Therapeutics, Inc. (Nasdaq: ATXI) from February 2019 to January 2022, and previously as Avenue's Vice President of Finance and Corporate Controller from August 2017, where he secured multiple equity financings and served in a leadership role on a complex, two-stage acquisition with future contingent value rights. Earlier he was Assistant Corporate Controller at Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) from October 2016 to July 2017, helping grow the finance and accounting department during the company's transition from a development-stage company to a fully integrated commercial organization.
Roles
Abeona Therapeutics Inc.
Chief Financial Officer · Current role
March 2022–present
Abeona Therapeutics Inc.
Chief Financial Officer
March 2022 - present
Avenue Therapeutics, Inc. (Nasdaq: ATXI)
Chief Financial Officer
February 2019 - January 2022
Avenue Therapeutics, Inc.
Vice President of Finance and Corporate Controller
August 2017 - February 2019
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT)
Assistant Corporate Controller
October 2016 - July 2017
Fixed Compensation
FY 2025
Salary
$475,903
ComponentAnnual base salary earned in FY2025
Bonus
$235,333
ComponentCash retention bonus paid June 23, 2025 to offset a 2022 equity shortfall versus recommended market grant
All other compensation
$14,000
ComponentEmployer matching contributions to the 401(k) Defined Contribution Plan
Total compensation
$1,734,865
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$173,229
Target Opportunity
—
PlanTarget-based cash incentive bonus earned with respect to FY2025
Stock awards
Stock awards
$836,400
FormRestricted stock awards, aggregate grant-date fair value computed in accordance with ASC 718